A screen test, prostate-specific antigen (PSA) blood test, followed by a biopsy can be used to detect prostate cancers when asymptomatic and localised within the prostate gland, but PSA is not a specific marker for prostate cancer and prostate biopsy is associated with adverse effects [2]. This evidence concerns the gene KLK3 and prostate carcinoma.